After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Allogene Therapeutics Inc is $328.11M. A total of 1.41 million shares were traded on the day, compared to an average of 2.82M shares.
In the most recent transaction, Beneski Benjamin Machinas sold 786 shares of ALLO for 1.22 per share on Nov 17 ’25. After the transaction, the SVP, Chief Technical Officer now owns 217,721 company shares. In a previous transaction on Nov 17 ’25, Beneski Benjamin Machinas bought 786 shares at 1.22 per share.
Among the insiders who sold shares, Parker Geoffrey M. disposed of 36,744 shares on Oct 21 ’25 at a per-share price of $1.26. This resulted in the CHIEF FINANCIAL OFFICER holding 1,276,796 shares of ALLO after the transaction. In another insider transaction, Parker Geoffrey M. bought 36,744 shares at $1.26 per share on Oct 21 ’25.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ALLO has a high of $3.78 and a low of $0.86.
As of this writing, ALLO has an earnings estimate of -$0.22 per share for the current quarter. EPS was calculated based on a consensus of 10.0 estimates, with a high estimate of -$0.17 per share and a lower estimate of -$0.42. The company reported an EPS of -$0.28 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $47.91M in liabilities at the time. Its Book Value Per Share was $1.41, while its Total Shareholder’s Equity was $925.20M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.27.
